KIRKLAND, Wash., Sept. 2, 2020 /PRNewswire/ -- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System.The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the primary cause of FMR in patients with mitral regurgitation grades 2+, 3+ and 4+.
"We would like to thank the Therapeutic Goods Administration for their partnership in the review and approval of the Carillon System in Australia," said Rick Wypych, Chief Executive Officer and President of Cardiac Dimensions. "This is a significant milestone as Australian patients with heart failure can now be treated earlier in their disease state with a minimally invasive treatment for mitral regurgitation."
An estimated 26 million people, worldwide, suffer from heart failureiand of those, approximately 70 percent have FMR. Heart failure is a significant clinical and economic burden with direct and indirect costs expected to grow to $70 billion by 2030.ii
"The availability of the Carillon System is an extremely exciting advancement for the medical community as this technology has the potential to help millions of patients suffering from heart failure and FMR," commented David Kaye, MD, Director of Cardiology at The Alfred Hospital, Melbourne, Australia. "The Carillon System provides a new, non-surgical method to correct a fundamental problem with the mitral valve in patients with heart failure. This approach has been shown to reduce mitral regurgitation and to favorably impact the left ventricle (LV). This is significant because a reduction in LV enlargement in heart failure is known to be associated with positive patient outcomes."
The Carillon System is placed using a non-surgical, minimally invasive (catheter-based) technique in a vein on the outside of the heart that is adjacent to the mitral valve. This procedure is designed to reshape the mitral valve, reduce valve leakage, and thus reduce mitral regurgitation and induce favorable remodeling.
The TGA's approval was based on the combined efficacy and safety results from several Cardiac Dimensions' studies including the most recent REDUCE FMR study. Treatment with the Carillon Mitral Contour System in these studies consistently demonstrated a significant decrease in regurgitant volume and left ventricular volumes. These changes were associated with reduced heart failure symptoms and improved quality of life.
"M.H. Carnegie & Co. and Hostplus, a large investor in our medical device initiative, recognized early on the importance of the Carillon System to patients and have been a significant supporter of the therapy and the company during their journey," said Mark Carnegie of M.H. Carnegie & Co. "We're excited now that the company has approval in Australia and look forward to the benefits it brings this underserved patient population."
About the Carillon Mitral Contour System
The Carillon System offers a simple right heart approach to transcatheter mitral valve repair (TMVr) designed to reshape the anatomy and function of the mitral apparatus from the coronary sinus. Distal and proximal anchors, connected by a shaping ribbon, utilize the heart's venous anatomy to cinch the mitral apparatus, without compromising the valve or future treatment options.iii, ivThe Carillon System is designed to treat the primary cause of functional mitral regurgitation (FMR) in patients with MR grades 2+, 3+ and 4+ and is the first and only device to demonstrate a reduction in regurgitant volume and favorable left ventricular remodeling in a randomized sham-controlled clinical trial of percutaneous valve therapy.v,vi, vii The Carillon System is CE-marked (0344) and has been implanted in over 1,200 patients in the U.S., Europe, Australia, Turkey and the Middle East. The Carillon System is currently being studied in The CARILLON Trial pivotal trial and limited to investigational use in the United States.
About Cardiac Dimensions
Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions. Privately held, the company's lead investors include Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira Ventures and M.H. Carnegie & Co. Cardiac Dimensions is headquartered in Kirkland, Washington and has operations in the United States, Australia and Germany. For more information, visitcardiacdimensions.com.
iPonikowski P, Anker SD, AlHabib KF et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1:425.
iiHeidenreich PA, Albert NM, Allen LA, et al. Forecasting the Impact of Heart Failure in the United States. Circ Heart Fail. 2013;6(3):606-19.
iiiHoppe UC, Brandt MC, Degen H, et al. Percutaneous mitral annuloplasty device leaves free access to cardiac veins for resynchronization therapy. Catheter Cardiovasc Interv. 2009;74(3):506-11.
ivLatib, A. "Coronary Sinus Annuloplasty." New York, Montefiore Medical Center.
vLipiecki J, Siminiak T, Sievert H, et al. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. BMJ Open Heart. 2016; 3
viSiminiak T, et. al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: Results of the TITAN Trial. Eur J Heart Fail. 2012;14:931-38.
viiSievert, H. 2018. REDUCE-FMR: A Sham-controlled Randomized Trial of Transcatheter Indirect Mitral Annuloplasty in Heart Failure Patients with Functional Mitral Regurgitation. Presented at TCT 2018, San Diego, CA.
SOURCE Cardiac Dimensions
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... [Last Updated On: April 13th, 2018] [Originally Added On: April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health [Last Updated On: May 12th, 2018] [Originally Added On: May 12th, 2018]
- Ventricular septal defect - Wikipedia [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... [Last Updated On: July 7th, 2018] [Originally Added On: July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... [Last Updated On: July 17th, 2018] [Originally Added On: July 17th, 2018]
- Ventricular Remodeling | Profiles RNS [Last Updated On: July 24th, 2018] [Originally Added On: July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia [Last Updated On: August 20th, 2018] [Originally Added On: August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) [Last Updated On: September 24th, 2018] [Originally Added On: September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... [Last Updated On: November 25th, 2018] [Originally Added On: November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- TIMI Study Group - LEADERSHIP [Last Updated On: January 31st, 2019] [Originally Added On: January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... [Last Updated On: February 24th, 2019] [Originally Added On: February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network [Last Updated On: December 4th, 2019] [Originally Added On: December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance [Last Updated On: December 4th, 2019] [Originally Added On: December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist [Last Updated On: December 16th, 2019] [Originally Added On: December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News [Last Updated On: January 23rd, 2020] [Originally Added On: January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor [Last Updated On: January 23rd, 2020] [Originally Added On: January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances [Last Updated On: February 1st, 2020] [Originally Added On: February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor [Last Updated On: February 1st, 2020] [Originally Added On: February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... [Last Updated On: February 26th, 2020] [Originally Added On: February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance [Last Updated On: March 5th, 2020] [Originally Added On: March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... [Last Updated On: March 15th, 2020] [Originally Added On: March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance [Last Updated On: March 15th, 2020] [Originally Added On: March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... [Last Updated On: March 16th, 2020] [Originally Added On: March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal [Last Updated On: April 23rd, 2020] [Originally Added On: April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel [Last Updated On: June 12th, 2020] [Originally Added On: June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor [Last Updated On: June 12th, 2020] [Originally Added On: June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor [Last Updated On: June 12th, 2020] [Originally Added On: June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web [Last Updated On: August 29th, 2020] [Originally Added On: August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News [Last Updated On: September 3rd, 2020] [Originally Added On: September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape [Last Updated On: September 5th, 2020] [Originally Added On: September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex [Last Updated On: October 27th, 2020] [Originally Added On: October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire [Last Updated On: October 27th, 2020] [Originally Added On: October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser [Last Updated On: November 12th, 2020] [Originally Added On: November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... [Last Updated On: November 25th, 2020] [Originally Added On: November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances [Last Updated On: January 13th, 2021] [Originally Added On: January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor [Last Updated On: April 13th, 2021] [Originally Added On: April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire [Last Updated On: April 13th, 2021] [Originally Added On: April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press [Last Updated On: April 13th, 2021] [Originally Added On: April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times [Last Updated On: June 21st, 2021] [Originally Added On: June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network [Last Updated On: November 5th, 2021] [Originally Added On: November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape [Last Updated On: November 5th, 2021] [Originally Added On: November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... [Last Updated On: January 26th, 2022] [Originally Added On: January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire [Last Updated On: September 12th, 2022] [Originally Added On: September 12th, 2022]